Introduction {#S0001}
============

Multiple sclerosis (MS) is a debilitating disease, accompanied by neurological symptoms of varying severity, which over many years can result in chronic disability with a major impact on the quality of life (QOL) and productivity of patients.^[@CIT0001]^

Cost-effectiveness and cost-utility analyses (CEA/CUAs) are useful tools to assess the trade-off between the added costs and potential benefits (e.g., improved patient outcomes) of new therapies. A majority of the published CEA/CUA evaluations of disease-modifying drugs (DMDs) for MS have been conducted from perspectives outside Iran.^[@CIT0002]--[@CIT0008]^

The objective of this study was to adjust the US model to assess the cost-utility of 4 DMDs therapies versus symptom management in treating relapsing-remitting multiple sclerosis (RRMS) from the Iranian Ministry of Health (MoH) perspective in 2012.

Materials and Methods {#S0002}
=====================

A deterministic Markov model, programmed in TreeAge Pro 2011^®^, was created based on a previously published model.^[@CIT0009]^ Patients in the model transition monthly between the following Kurtzke\'s expanded disability status scale (EDSS) health states:EDSS 0.0--2.5: No or few limitations in mobilityEDSS 3.0--5.5: Moderate limitations in mobilityEDSS 6.0--7.5: Walking aid or wheelchair requiredEDSS 8.0--9.5: Restricted to bedRelapse EDSS 0.0--2.5: Relapse with a change in disability within EDSS 0.0--2.5Relapse EDSS 3.0--5.5: Relapse with a change in disability within EDSS 3.0--5.5EDSS 10: Death

Patients can remain in the current EDSS health state or transition to the next more severe EDSS health state as seen in other models.^[@CIT0007],\ [@CIT0010]--[@CIT0012]^ Probabilities of disease progression between EDSS levels and relapse are presented in [Table 1](#T0001){ref-type="table"}.

###### 

Summary of clinical parameters and values used in the model

  Parameter description                                                                          Value (plausible range)   Sources/assumptions
  ----------------------------------------------------------------- -------- ----------- ------- ------------------------- ---------------------
  Initial patient distribution among EDSS health states (%)                                                                
  EDSS 0.0--2.5                                                                                  26.4                      9
  EDSS 3.0--5.5                                                                                  58.7                      
  EDSS 6.0--7.5                                                                                  13.8                      
  EDSS 8.0--9.5                                                                                  1.1                       
  Monthly probability of disease progression (symptom management)                                                          
  EDSS 0.0--2.5 to 3.0--5.5                                                                      0.004438                  
  EDSS 3.0--5.5 to 6.0--7.5                                                                      0.009189                  9
  EDSS 6.0--7.5 to 8.0--9.5                                                                      0.003583                  
  EDSS 8.0--9.5 to 10 (death)                                                                    0.000952                  
  Monthly probability of relapse (symptom management)                                            0.075500                  
  Utility weights:                                                                                                         
  EDSS 0.0--2.5                                                                                  0.824                     9, 11, 17
  EDSS 3.0--5.5                                                                                  0.679                     
  EDSS 6.0--7.5                                                                                  0.533                     
  EDSS 8.0--9.5                                                                                  0.491                     
  Utility decrement associated with relapse                                                      0.094                     
  Treatment Effects,% reduction in:                                 Avonex   Betaferon   Rebif   CinnoVex                  
  Probability of disease progression                                37       29          30      34                        9, 18, 19
  Probability of relapse                                            32       34          33      31                        

EDSS: Expanded disability status scale

The model is run until all patient progress to death as a result of MS or as a result of all other causes. Costs and outcomes were estimated from the Iranian MoH perspectives and were discounted at 7.2% per annum. All costs are reported in USD, year 2011 values. ([Table 2](#T0002){ref-type="table"})

###### 

Summary of cost and lost worker productivity parameters and values used in the model (USD, year 2011 values)

  Parameter description                             Value   Sources/assumptions
  ------------------------------------------------- ------- --------------------------------------------------
  Monthly per prescription drug acquisition costs           
  Avonex                                            800     
  Betaferon                                         1770    Iranian FDA list drugs
  Rebif                                             1500    
  CinnoVex                                          311     
  Monthly MS-related health-state costs                     
  EDSS 0.0--2.5                                     18      
  EDSS 3.0--5.5                                     22      
  EDSS 6.0--7.5                                     55      Patient files and the Tariff Book, questionnaire
  EDSS 8.0--9.5                                     73      
  relapse EDSS 0.0--2.5                             138     
  relapse EDSS 3.0--5.5                             152     
  Monthly cost of lost worker productivity                  
  Symptom management                                84      
  Avonex                                            77      Patient employment records,
  Betaferon                                         75      questionnaire
  Rebif                                             76      
  CinnoVex                                          75      

EDSS: Expanded disability status scale

Patients were recruited sequentially on presentation to the MS Center of the Shahid Beheshti University of Medical Sciences and the study population represented a cross-section of the MS population of the area. Patients were eligible for inclusion into the study if they had clinically definite MS based on the McDonald criteria.^[@CIT0012]^

CUA is aimed at calculating the ratio of the difference in terms of both costs (incremental cost or ΔC) and quality adjusted life years (incremental QALYs or ΔQALYs) between alternative health care programs (i.e. A vs. B). The ratio of incremental cost to incremental QALYs \[i.e. (Cost A -- Cost B)/ (QALYs A -- QALYs B)\] is called incremental cost-effectiveness ratio (ICER; i.e. ΔC/ΔQALYs).^[@CIT0014],\ [@CIT0015]^ In general, ICER means the cost of obtaining an incremental effectiveness unit (e.g., an incremental QALY) by adopting the health care program under investigation instead of comparator.^[@CIT0013],\ [@CIT0014]^

Results {#S0003}
=======

Total costs per patient over the time horizon of a patient\'s lifetime were estimated at 20285, 144194, 299279, 251255 and 69796 USD for symptom management, Avonex, Betaferon, Rebif and CinnoVex, respectively ([Table 3](#T0003){ref-type="table"}). Higher total costs for DMDs were a result of drug costs. Lost worker productivity costs for patients treated with DMDs tended to be lower than for patients receiving symptom management as a result of patients being able to stay in the workforce longer because they remained longer in EDSS 0.0--5.5 health states.

###### 

Base-case discounted costs per patient (lifetime perspective)

  Cost Component                                    Symptom Management   Avonex    Betaferon   Rebif     CinnoVex
  ------------------------------------------------- -------------------- --------- ----------- --------- ----------
  Lifetime drug acquisition costs                   \-                   125280    280581      232740    50448
  (average no. of years on therapy)                 (13.17)              (13.05)   (13.21)     (12.93)   (13.50)
  MS-related medical costs                          7052                 6873      6857        6732      7167
  Lost worker productivity costs                    13233                12041     11841       11783     12181
  Total costs                                       20285                144194    299279      251255    69796
  Average no. of years spent in EDSS 0.0-5.5        12.28                14.71     14.54       14.29     14.35
  Average no. of years spent relapse-free           11.42                14.24     14.15       13.98     13.27
  Life years                                        14.791               14.818    14.817      14.815    14.797
  QALYs                                             9.081                9.285     9.284       9.279     9.130
  Incremental cost per year spent in EDSS 0.0-5.5   \-                   50991     123449      114910    23918
  Incremental cost per year spent relapse-free      \-                   43939     102196      90223     26763
  Incremental cost per life-year gained             \-                   4589222   10730538    9623750   8251833
  Incremental cost per QALY gained                  \-                   607397    1374355     1166515   1010429

EDSS: Expanded disability status scale

Lifetime drug acquisition costs were the largest cost component (approximately 86-93% of total costs in the DMDs arms), followed by the cost of lost worker productivity costs (approximately 65% of total costs in the symptom management arm and 4-17% of total costs in the DMDs arms).

Total costs for patients receiving CinnoVex continued to be lower than for patients receiving other DMDs. Because of treatment with DMDs, patients spent more time in the lower EDSS health states (EDSS 0.0--5.5) and more time being relapse-free compared with those who received symptom management alone. Outcomes over the lifetime horizon assessed in the model were similar across the 4 DMDs therapies and were generally improved compared to outcomes with symptom management ([Table 3](#T0003){ref-type="table"}).

Patients receiving DMDs benefited from more QALYs compared with patients receiving symptom management alone. Patients receiving Avonex incurred higher additional QALYs than patients receiving other DMDs, although the difference was small. As a result, the incremental cost per QALY for patients receiving Avonex, Betaferon, Rebif and CinnoVex was 607397, 1374355, 1166515 and 1010429 USD, respectively, when compared with symptom management. Because patients receiving Avonex incurred slightly higher QALYs than patients receiving other DMDs, treatment with Avonex dominated other DMDs in Iran.

Discussion {#S0004}
==========

The present analysis is the first economic model in MS to (1) incorporate long-term data on treatment effects,and (2) present results in terms of cost-utility (cost per QALY gained) and cost-effectiveness (e.g., cost per year spent relapse free or cost per year spent in less severe disease health states).

Models indicated that the potential long-term outcomes of treating RRMS patients with DMDs were increased clinical benefits compared with symptom management, albeit at higher costs. In long-term, patients who were treated with Avonex could expect overall greater benefit compared with patients treated with other DMDs. However, the difference in benefit was small. Thus, patients may consider the overall clinical benefit of treatment with DMDs to be similar, whereas costs for patients receiving CinnoVex were observed to be lower. Among the 4 DMDs therapies used to manage MS compared to symptom management, Avonex was the best strategy in terms of outcomes and costs.

An overarching concern of this analysis may be that incremental costs per QALY (607397 for Avonex, 1374355 for Betaferon, 1166515 for Rebif and 1010429 USD for CinnoVex) were greater than 50000 USD (incremental costs per QALY well above the arbitrary and commonly referenced benchmark of 50000 USD per QALY) for both disease-modifying therapies compared with symptom management.^[@CIT0015]--[@CIT0019]^ This is attributable to the high cost of disease-modifying therapies in MS as well as the chronic nature of the disease and the fact that these therapies do not significantly impact survival in combination with the impact on patient well-being (i.e. utilities). Thus, the differences in the denominator of the incremental cost per QALY are very small, which results in a large ratio. This phenomenon is similar to results reported in other published cost-utility analyses of disease-modifying therapies in MS.^[@CIT0007],\ [@CIT0009],\ [@CIT0010]^

In a previous US-based cost-effectiveness model conducted by Prosser et al.,^[@CIT0010]^ the authors concluded that Avonex compared with no treatment (i.e., symptomatic treatment) yielded the largest gain in QALYs with an ICER between \$1.8 and \$2.2 million per QALY gained. These results were significantly similarto the current analysis.

Sensitivity analyses conducted in the Prosser et al. model,^[@CIT0010]^ the current analysis, and other MS models have clearly indicated that results are influenced by time horizon, with shorter time horizons associated with less favorable ICERs^[@CIT0009]^ and other models^[@CIT0002],\ [@CIT0007]^ and longer time horizons associated with more favorable ICERs (e.g., current analysis and the study by Nuijten and Hutton^[@CIT0004]^. As part of this analysis, we recognized some limitations. Foremost was the lack of data on change in clinical efficacy and discontinuation over time for patients receiving DMDs.

Conclusion {#S0005}
==========

The use of each DMD in patients with RRMS was associated with increased benefits compared with symptom management alone, albeit at higher costs. Sensitivity analyses indicated that cost-utility was sensitive to changes in a number of key parameters; thus, changes in these key parameters would be likely to influence the estimated cost-utility results. Although the results of this analysis provide decision makers with health economic evidence on the use of disease modifying therapies, MS is a heterogeneous disease, and physicians must therefore select the most appropriate treatment based on the disease characteristics of individual patients.
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